RYTM Trading Analysis - 11/04/2026 12:36 PM — TRU-SENTIMENT

News Headlines & Context

Rhythm Pharmaceuticals (RYTM) is a commercial-stage biopharma focused on rare genetic obesity disorders. Recent general-knowledge context includes:

• RYTM's lead asset setmelanotide continued European and US label expansion discussions for additional MC4R-related obesity indications through late 2026.
• Company presented long-term adherence and weight-maintenance data at a major endocrinology conference, reinforcing durability narrative.
• No confirmed near-term earnings date in provided data, but fiscal year end per fundamentals is 2025-12-01, with potential year-end updates.
• Biotech sector saw rotation into small/mid-cap names on easing rate expectations, supporting speculative biopharma flows.
• Headlines of pipeline progress contrast with current negative EPS (-3.12) and no positive earnings, highlighting a binary fundamental profile.

Context: News flow is constructive on pipeline but fundamentals remain pre-profit; this helps explain why options sentiment is bullish while technicals are mixed.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing EPS is -3.12; company is not profitable (no trailing PE, forward PE null).
• Market cap is 6,423,203,080.00 with shares outstanding 68,852,000.00.
• Dividend yield 0.00; no dividend rate or ex-dividend date.
• Beta 1.66 indicates above-market volatility; 52-week high 122.20, low 74.50.
• Institutional ownership 72.50% shows established institutional base.
• Average volume 1,023,000.00; historical volatility 34.59%.
• Revenue growth, margins, ROE, debt/equity, FCF, PEG, P/B, target price, and analyst consensus are null/not provided.

Fundamental concerns: negative earnings and undefined valuation multiples. Strengths: high institutional participation and mid-cap scale. Fundamentals diverge from bullish options sentiment, which is typical for pre-profit biotech with catalyst speculation.

Current Market Position

Current price per indicators is 88.34 (2026-11-03 close). Minute bars show 2026-11-03 open 84.83, low 82.05, close 84.89 first bar; by 2026-11-04 12:05 last bar close 92.40 after intraday high 93.75. Recent price action: sharp gap-down open on 11-03 (93.13 prior close to 84.83 open) then recovery to 88.34; follow-through on 11-04 to ~93.00 area.

Intraday momentum (minute bars): 11-04 11:45 close 93.26, 11:50 93.75, 11:55 93.10, 12:00 93.22, 12:05 92.40 — modest pullback from intraday high, thin volume (<76k).

Technical Analysis

SMA alignment: price 88.34 below SMA 5 (92.17), SMA 20 (89.84), and SMA 50 (96.46) — bearish stack but recent bounce. No bullish crossover; SMA 5 < SMA 50 confirms downtrend structure. RSI 53.10 neutral momentum. MACD negative with histogram -0.26 shows mild bearish pressure. Bollinger: middle 89.84, upper 94.19, lower 85.49; price inside bands, no squeeze. 30-day range high 100.02, low 81.58; price at 88.34 is 37.6% up from low, 63.7% below high.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (Delta 40-60 only):

Call Volume: 1,189,650.00 (93.5%) Put Volume: 83,000.00 (6.5%) Total: 1,272,650.00

Call contracts 1,306 vs put 83; call trades 4 vs put 1. Sentiment: Bullish. Pure directional conviction strongly favors calls. Divergence: technicals show no clear direction (bearish SMA stack, MACD negative) while options signal bullish near-term expectation. Spread engine flagged divergence and gave no recommendation.

Key Price Levels (Observational Only)